SCI Abstract

search
+
Mammographic density and breast cancer pathological subtypes by menopausal status and body mass index
Mammographic density and breast cancer pathological subtypes by menopausal status and body mass index
Mammographic density (MD) is an established biomarker of breast cancer (BC) risk. However, its relationship to BC patholog...
Preclinical evaluation of 64Cu-labeled cetuximab in immuno-PET for detecting sentinel lymph node metastasis in epidermal growth factor receptor-positive breast cancer
Preclinical evaluation of 64Cu-labeled cetuximab in immuno-PET for detecting sentinel lymph node metastasis in epidermal growth factor receptor-positive breast cancer
Despite advances in breast cancer imaging, reliable detection of sentinel lymph node (SLN) metastasis remains challenging....
Development of a deep learning-based model for guiding a dissection during robotic breast surgery
Development of a deep learning-based model for guiding a dissection during robotic breast surgery
Traditional surgical education is based on observation and assistance in surgical practice. Recently introduced deep learn...
Cellular senescence predicts breast cancer risk from benign breast disease biopsy images
Cellular senescence predicts breast cancer risk from benign breast disease biopsy images
Each year, millions of women undergo breast biopsies. Of these, 80% are negative for malignancy but some may be at elevate...
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study
Molecular determinants of response to neoadjuvant pembrolizumab plus chemotherapy in patients with high-risk, early-stage, triple-negative breast cancer: exploratory analysis of the open-label, multicohort phase 1b KEYNOTE-173 study
The multicohort, open-label, phase 1b KEYNOTE-173 study was conducted to investigate pembrolizumab plus chemotherapy as ne...
Breast tumors from ATM pathogenic variant carriers display a specific genome-wide DNA methylation profile
Breast tumors from ATM pathogenic variant carriers display a specific genome-wide DNA methylation profile
The ataxia-telangiectasia mutated (ATM) kinase phosphorylates and activates several downstream targets that are essential ...
The deubiquitinating enzyme USP11 regulates breast cancer progression by stabilizing PGAM5
The deubiquitinating enzyme USP11 regulates breast cancer progression by stabilizing PGAM5
Breast cancer is common worldwide. Phosphoglycerate mutase 5 (PGAM5) belongs to the phosphoglycerate mutase family and pla...
Deep learning applications in breast cancer histopathological imaging: diagnosis, treatment, and prognosis
Deep learning applications in breast cancer histopathological imaging: diagnosis, treatment, and prognosis
Breast cancer is the most common malignant tumor among women worldwide and remains one of the leading causes of death amon...
WHO-recommended levels of physical activity in relation to mammographic breast density, mammographic tumor appearance, and mode of detection of breast cancer
WHO-recommended levels of physical activity in relation to mammographic breast density, mammographic tumor appearance, and mode of detection of breast cancer
Despite known benefits of physical activity in reducing breast cancer risk, its impact on mammographic characteristics rem...
On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer
On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer
Patients with pathologic complete response (pCR) to neoadjuvant chemotherapy for invasive breast cancer (BC) have better o...
Reproductive factors and mammographic density within the International Consortium of Mammographic Density: A cross-sectional study
Reproductive factors and mammographic density within the International Consortium of Mammographic Density: A cross-sectional study
Elevated mammographic density (MD) for a woman’s age and body mass index (BMI) is an established breast cancer risk ...
Alpha-6 integrin deletion delays the formation of Brca1/p53-deficient basal-like breast tumors by restricting luminal progenitor cell expansion
Alpha-6 integrin deletion delays the formation of Brca1/p53-deficient basal-like breast tumors by restricting luminal progenitor cell expansion
The aberrant amplification of mammary luminal progenitors is at the origin of basal-like breast cancers associated with BR...
Inflammation at diagnosis and cognitive impairment two years later in breast cancer patients from the Canto-Cog study
Inflammation at diagnosis and cognitive impairment two years later in breast cancer patients from the Canto-Cog study
Inflammation could be related to cancer-related cognitive impairment (CRCI) and might be used as a predictive marker of lo...
Increased expression of REG3A promotes tumorigenic behavior in triple negative breast cancer cells
Increased expression of REG3A promotes tumorigenic behavior in triple negative breast cancer cells
Identifying new targets in triple negative breast cancer (TNBC) remains critical. REG3A (regenerating islet-derived protei...
NSUN2/YBX1 promotes the progression of breast cancer by enhancing HGH1 mRNA stability through m5C methylation
NSUN2/YBX1 promotes the progression of breast cancer by enhancing HGH1 mRNA stability through m5C methylation
RNA m5C methylation has been extensively implicated in the occurrence and development of tumors. As the main methyltransfe...
Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer
Lasofoxifene as a potential treatment for aromatase inhibitor-resistant ER-positive breast cancer
Breast cancers treated with aromatase inhibitors (AIs) can develop AI resistance, which is often driven by estrogen recept...
ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis
ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis
Human epidermal growth factor receptor 2 (HER2)-positive breast cancer accounts for about 20% of all breast cancer cases a...
Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response
Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response
Since breast cancer patients respond diversely to immunotherapy, there is an urgent need to explore novel biomarkers to pr...
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer
TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer
Patients with inflammatory breast cancer (IBC) have overall poor clinical outcomes, with triple-negative IBC (TN-IBC) bein...
Improving lesion detection in mammograms by leveraging a Cycle-GAN-based lesion remover
Improving lesion detection in mammograms by leveraging a Cycle-GAN-based lesion remover
The wide heterogeneity in the appearance of breast lesions and normal breast structures can confuse computerized detection...
Molecular subtypes of breast cancer predicting clinical benefits of radiotherapy after breast-conserving surgery: a propensity-score-matched cohort study
Molecular subtypes of breast cancer predicting clinical benefits of radiotherapy after breast-conserving surgery: a propensity-score-matched cohort study
Based on the molecular expression of cancer cells, molecular subtypes of breast cancer have been applied to classify patie...
Key regulator PNPLA8 drives phospholipid reprogramming induced proliferation and migration in triple-negative breast cancer
Key regulator PNPLA8 drives phospholipid reprogramming induced proliferation and migration in triple-negative breast cancer
Triple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and leads to the poorest patient outcome...
Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer
Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer
The aim of the study was to compare the difference in survival between invasive ductal (IDC) and lobular carcinoma (ILC). ...
Development and evaluation of a method to assess breast cancer risk using a longitudinal history of mammographic density: a cohort study
Development and evaluation of a method to assess breast cancer risk using a longitudinal history of mammographic density: a cohort study
Women with dense breasts have an increased risk of breast cancer. However, breast density is measured with variability, wh...
Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
Integrative whole-genome and transcriptome analysis of HER2-amplified metastatic breast cancer
In breast cancer, the advent of anti-HER2 therapies has made HER2+ tumors a highly relevant subgroup. However, the exact c...
The BET degrader ZBC260 suppresses stemness and tumorigenesis and promotes differentiation in triple-negative breast cancer by disrupting inflammatory signaling
The BET degrader ZBC260 suppresses stemness and tumorigenesis and promotes differentiation in triple-negative breast cancer by disrupting inflammatory signaling
Breast cancer stem cells (BCSCs) are resistant to standard therapies, facilitate tumor dissemination, and contribute to re...
Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer
Multimodal prediction of neoadjuvant treatment outcome by serial FDG PET and MRI in women with locally advanced breast cancer
To investigate combined MRI and 18F-FDG PET for assessing breast tumor metabolism/perfusion mismatch and predicting pathol...
AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer
AMEERA-4: a randomized, preoperative window-of-opportunity study of amcenestrant versus letrozole in early breast cancer
Window-of-opportunity (WOO) studies provide insights into the clinical activity of new drugs in breast cancer. AMEERA-4 (N...
Blocking channels to metastasis: targeting sodium transport in breast cancer
Blocking channels to metastasis: targeting sodium transport in breast cancer
The development of therapies that can suppress invasion and prevent metastasis, ‘anti-metastatic drugs’, is an...
PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning
PROACTING: predicting pathological complete response to neoadjuvant chemotherapy in breast cancer from routine diagnostic histopathology biopsies with deep learning
Invasive breast cancer patients are increasingly being treated with neoadjuvant chemotherapy; however, only a fraction of ...
Load More
format_indent_increase